Chapter 3 48 Table 3. Overview of major bleeding and thromboembolic events in large randomized controlled trials comparing periprocedural NOAC and VKA in patients undergoing catheter ablation of AF Trial BARC 3–5 bleedings ISTH major bleeding Thrombo-embolic events RE-CIRCUIT (5) – VKA, N = 318 NA 6.9% 0.3% RE-CIRCUIT (5) – uninterrupted dabigatran, N = 317 NA 1.6%* 0.0% VENTURE-AF (6) – VKA, N = 124 NA 0.8% 0.8% VENTURE-AF (6) – uninterrupted rivaroxaban, N = 124 NA 0.0% 0.0% AXAFA (12) – VKA, N = 315 4.1% 4.4% 0.0% AXAFA (12) – uninterrupted apixaban, N = 318 2.5% 3.1% 0.6% ABRIDGE-J (13) – VKA, N = 222 NA 5.0% 0.5% ABRIDGE-J (13) – interrupted dabigatran, N = 220 NA 1.4%* 0.0% AEIOU (21) – uninterrupted apixaban, N = 150 1.3% NA 0.7% AEIOU (21) – interrupted apixaban, N = 145 2.1% NA 0.7% *Statistically significant difference in comparison to the VKA group. BARC = Bleeding Academic Research Consortium, ISTH = International Society on Thrombosis and Haemostasis, NA = not available, NOAC = novel oral anticoagulant, TIA = transient ischemic attack, VKA= vitamin K antagonist Figures Figure 1. Proportion of periprocedural NOAC and VKA use over the years
RkJQdWJsaXNoZXIy MTk4NDMw